Heron Therapeutics: ASCO Breast Cancer Symposium (Heron Therapeutics) - Oct 10, 2015 - "AFP530, administered with fosaprepitant+ dexamethasone, provided superior CR in delayed-phase CINV following HEC versus a standard 3-drug regimen of ondansetron with fosaprepitant + dexamethasone"; "The APF530 regimen was assoicated with a clinical benefit over the ondansetron regimen in nausea control, rescue medication use, and patient satisfaction"; "This was the first prospective. 3-drug versus 3-drug efficacy trial for the prevention of CINV"
P3 data • Oncology
|